1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6BB8D1A7325F647C365258336003EE850
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/wp-effectively-launching-oncology-products-in-us-market?OpenDocument&Email=
18
19OpenDocument&Email=
2044.210.149.205
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25RAS




Products & Services Product Launch Resource Allocation

White Paper: Effectively Launching Oncology Products in the U.S. Market

Whitepaper Image

ID: BEB-79


Pages/Slides: 7


Published: 2019


Delivery Format: PDF


 

License Options:


Download White Paper

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
In the highly regulated and extremely competitive US Oncology market, it is critical that pharma and biotech players understand the investment and staffing levels needed for success today in key activities and functions before, during, and after the launch of a new oncology product.

Best Practices, LLC has conducted exclusive research and analysis to examine oncology product investment levels for 12 companies and 20 U.S. oncology launches across pre-launch, launch and post-launch periods.

This white paper provides evidence-based benchmarks around investment, staffing and timing requirements to effectively launch new oncology drugs in the U.S. market.

Key topics examined in this white paper include:
  • Pre-, Launch, and Post-Launch Phase Investments
  • Pre-, Launch, and Post-Launch Phase Staffing
  • Peak-Year Sales Forecasting
  • Key Activities and Programs
  • Multi-Indication and Portfolio Leverage
Industries Profiled:
Consulting; Biotech; Medical Device; Pharmaceutical; Diagnostic; Clinical Research; Communications


Companies Profiled:
Pharma; Biotech Companies